Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA panel says benefits outweigh risks for Lilly's lung-cancer drug
FDA panel says benefits outweigh risks for Lilly's lung-cancer drug
FDA panel says benefits outweigh risks for Lilly's lung-cancer drug
Submitted by
admin
on July 9, 2015 - 9:51pm
Source:
Medical Marketing and Media
News Tags:
FDA
advisory panels
Eli Lilly
necitumumab
lung cancer
Headline:
FDA panel says benefits outweigh risks for Lilly's lung-cancer drug
Do Not Allow Advertisers to Use My Personal information
